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Abstract
Background: MicroRNAs have been widely-studied with regard to their aberrant expression and high correlation with
tumorigenesis and progression in various solid tumors. With the major goal of assessing gonadotropin (luteinizing
hormone, LH) contributions to LH receptor (LHR)-positive ovarian cancer cells, we have conducted a genome-wide
transcriptomic analysis on human epithelial ovarian cancer cells to identify the microRNA-associated cellular response to LH-
mediated activation of LHR.
Methods: Human ovarian cancer cells (SKOV3) were chosen as negative control (LHR2) and stably transfected to express
functional LHR (LHR+), followed by incubation with LH (0–20 h). At different times of LH-mediated activation of LHR the
cancer cells were analyzed by a high-density Ovarian Cancer Disease-Specific-Array (DSA, ALMACTM), which profiled
,100,000 transcripts with ,400 non-coding microRNAs.
Findings: In total, 65 microRNAs were identified to exhibit differential expression in either LHR expressing SKOV3 cells or LH-
treated cells, a few of which have been found in the genomic fragile regions that are associated with abnormal deletion or
amplification in cancer, such as miR-21, miR-101-1, miR-210 and miR-301a. By incorporating the dramatic expression
changes observed in mRNAs, strong microRNA/mRNA regulatory pairs were predicted through statistical analyses coupled
with collective computational prediction. The role of each microRNA was then determined through a functional analysis
based on the highly-confident microRNA/mRNA pairs.
Conclusion: The overall impact on the transcriptome-level expression indicates that LH may regulate apoptosis and cell
growth of LHR+ SKOV3 cells, particularly by reducing cancer cell proliferation, with some microRNAs involved in regulatory
roles.
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Introduction
Ovarian cancer, the most lethal gynecological cancer and
second only to endometrial cancer in the number of female
reproductive track and organ cases diagnosed, led to approxi-
mately 21,880 new cases in the U.S. in 2010 with about 13,850
deaths [1]. The high morbidity is attributable in large part to a
lack of specific symptoms, thus delaying prognosis until advanced
stages of the disease. The 5-year survival rate of ovarian cancer in
later stages is 16–28% according to the International Federation of
Gynecology and Obstetrics [2]. Consequently, the majority of
ovarian cancer research has been focused on discovering screening
methods for early diagnosis and identifying the possible contrib-
uting factors for prevention of the disease.
A high correlation between ovarian cancer risk and altered
reproductive cycles has been reported in many clinical studies. For
example a higher risk is associated with peri- or post-menopause
[3] and incidences of infertility [4], while a decreased risk
correlates with pregnancy, oral contraceptive use, hysterectomy
and tubal ligation [4]. In addition, the elevated level of the
gonadotropins, luteinizing hormone (LH) and follicle-stimulating
hormone (FSH), was consistently found in cysts and the peritoneal
fluid of patients with ovarian cancer or borderline ovarian tumors,
compared to benign cysts or benign tumors [5], which has
attracted considerable attention, along with the status (positive or
negative) of the LH receptor (LHR), a member of the G protein-
coupled receptor family, in the cancer. There are suggestions that
LH could potentially serve as a cause or contributory factor to the
development or progression of ovarian cancer [6,7], while other
clinical reports show that there are no clear trends that using
gonadotropins to treat infertility will increase the risk of ovarian
cancer [8,9]. With such controversy [10,11,12,13], elucidation of
the downstream processes of LHR is imperative to discerning the
ramifications of increasing levels of LH in LHR+ cancer cells.
We have reported earlier [14] that the phenotypes of the LHR+
cells, but not the LHR- cells, exhibited reduced proliferation,
migratory and invasive properties in response to LH, and have
shown elsewhere the consequent changes in transcriptomic level
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expression [15]. The present study is focused on elucidating the
effects of LH on microRNA expression and regulation. This class
of small non-coding RNAs has recently gained considerable
interest in their involvement in cancer development and
progression via regulation of key cancer genes [16,17]. Many
microRNAs are found to be androgen related, and their
deregulation has correlated highly with initiation, progression
and prognosis of human cancers [18,19,20,21,22,23,24,25]. Given
the hypothesis that many of the myriad changes can be observed
from gene expression profiles of LH-mediated LHR activation in a
human ovarian cancer cell line (SKOV3), we applied a large-scale
transcriptomic analysis on the cells using an ovarian disease-
specific array. Our present analyses include three major steps: a)
comparative analysis on microRNA and mRNA expression in
response to LHR expression and activation in SKOV3 cells, b)
computational prediction of microRNA/mRNA regulation pairs,
in conjunction with experimental validated information and c)
functional analysis on target mRNAs to infer the major role of
their regulatory microRNA.
Materials and Methods
Choice of Cells and Microarray Analysis via Ovarian-
Cancer-Specific Array
The human SKOV3 ovarian carcinoma cell line [14], which
does not express LHR, was chosen as a negative control in this
study. The cells were stably transfected to express about 12,000
LHRs per cell, and the hormone binding affinity (Kd) of human
chorionic gonadotropin (CG) was 0.3 nM [14]. Human LH and
CG were obtained from Dr. A.F. Parlow (National Hormone and
Peptide Program, Torrance, CA). Total RNA was extracted from
the cells following the same protocol described elsewhere [14,15]
and then subjected to microarray analysis using the Almac
Diagnostic Ovarian Cancer DSATM research tool (Durham, NC).
Detailed procedures can be found at http://www.almacgroup.
com. The tailored ovarian-cancer array measures over 100,000
transcripts on one chip, including those solely expressed in ovary
and large numbers of novel ones that are not included in other
standard microarrays (e.g. tissue or disease-specific splice variants,
inherent antisense transcripts, and non-coding RNA obtained by
the in-house sequencing analysis at Almac). The comparison of the
array content between DSA and others can be found at http://
www.almacgroup.com/wp-content/uploads/Ovarian_Cancer_
DSA_techsheet2.pdf. Expression profiling was done on the control
SKOV3 cells, the LHR+ SKOV3 cells, and the LHR+ cells
incubated with LH for 1, 4, 8, and 20 hours [14], respectively, with
three replicates for each of these six variable groups. All data is
MIAME compliant and the raw data has been deposited in the
GEO database with accession number GSE27328.
Data Processing and Statistical Analysis
Since the ovarian DSA is a high-density platform including only
perfect match (PM) probes, the transcript expression was computed
using the PM-only normalization algorithm designed by Almac
Diagnostics (http://csbl.bmb.uga.edu/,juancui/Publications/
OvCan2011/PMonlyQC-documentation.pdf), which is similar
to MAS5 (Affymetrix). Transcripts with the maximum intensity
among all 18 samples lower than 10 were removed due to the
extremely low signal-to-noise ratio, and the geometric mean
expression of each transcript was calculated from the triplicates
in each group. Through statistical analyses with ANOVA and
Mann-Whitney test, only genes with a differential expression
change of more than 1.5-fold, with the P-value,= 0.05 adjusted
for multiple test by R package, were accepted for further analysis.
microRNA Target Prediction
MiRanda [26] and TargetScan [27] were used for predicting
the microRNA targets from the complete human genome. In
addition, the Spearman’s rank Rho coefficient between expression
levels of the microRNA and their targets was calculated based on
the following. Given Xi and Yi with i=1..n representing the
expression profiles of microRNA and mRNA, where n= 6
represents six distinct cellular states in order of LHR2,
LHR+,LH1, LH4, LH8 and LH20. The expression level was
then converted to ranks xi, and yi, respectively. The difference,
di = xi2yi, between the ranks of each observation was calculated,
and the coefficient is given by rho~1{
6
P
d2i
n(n2{1)
, where rho.0,
rho,0 and rho = 0 represent a positive, negative or no regulatory
effect between microRNA and mRNA. Given the Null hypothesis
H0 that xi and yi are independent, a two-tailed test was conducted
where the p-value is given as p{value~2:P(Z§ rj j ffiffiffiffiffiffiffiffiffiffin{1p ).
Those correlated pairs with modestly relaxed significance
(|rho|.0.8, p-value,=0.05) were the focus for further analysis.
Results
Altered microRNA and mRNA Expression Associated with
LHR Expression and Activation
Out of 132 microRNAs that were selectively profiled on the
array, 65 were identified to exhibit differential expression. Among
them, 17 are differential in LHR+ SKOV3 cells vs LHR- SKOV3
cells, i.e. negative control, including six upregulated (miR-101-1, -
101-2, -199b, -559, -573 and -7-3) and 11 downregulated (miR-
103-2, -200c, -151, -29c, -301b, -548a2, -552, -561, -566, -613 and
-642) (Table S1a). Following incubation with LH, 57 microRNAs
were differentially expressed, including the most highly expressed
microRNAs, miR-21, -200c, -593, -103-1 and -124-3 (Table S1b).
The details of microRNA information were obtained from
miRBase [28]. Of the 65 microRNAs, 19 are overlapping with
intergenic regions, 45 are overlapping with introns and one with
an exon, while 34 were found on the reverse strand (Table S2).
Gene loci were then obtained from Ensemble (hg18). Figure 1
shows the mapping of microRNAs to the human genome.
According to the microRNA clusters annotation in miRBase, i.e.
neighboring microRNAs within the pre-defined distance of 10 kb,
seven clusters were identified due to their inclusion of at least one
differentially expressed microRNA, namely miR-93, -301b, -200c,
-425, -29, -449b and -30e. Table S2 shows the impacted regions
with the differentially expressed microRNAs within a less restricted
distance range. Some of the differentially expressed microRNAs
have been aligned to fragile sites of the human genome where the
genomic variants were evidently associated with certain types of
cancer [29,30]. For example, the loss of 11p15 (covering miR-210)
is found in ovarian cancer [31] and 17q23 (covering miR-301a
and miR-21) is amplified in breast cancer [32], as well as those
reported in [33,34]. It should be noted that the SKOV3 cancer
cells may have already undergone some copying abnormalities,
such as the amplification of miR-21 and the loss of miR-210,
which may contribute to the observed gene expression level in the
control cancer cells. Although this cannot be determined from the
present data, our question here, instead, is whether or not LH
induces further transcriptional regulation on any of these
microRNAs.
Through the same differential analysis, we have identified 2,210
up-regulated and 4,297 down-regulated mRNAs in LHR+
SKOV3 cells, respectively. The expression change distribution is
given in Figure 2. These genes are intimately involved in cell
division, DNA replication and transcription, while the genes
MiRNA Expression in Ovarian Carcinoma with LH
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involved with carbohydrate transport/metabolism and lipid
metabolism are only reflected by down-regulated genes. During
the 20 h exposure to LH, a total of 14,903 mRNAs exhibited
elevated expression at one of the time points, which extend the
above functions to posttranslational modification, RNA processing
and modification, intracellular trafficking and secretion, signal
transduction mechanisms and coenzyme metabolism, while 10,389
mRNAs were down-regulated, reflecting the cellular defense
mechanism. The enriched pathway analysis shows that LHR
expression in SKOV3 cells may have a positive impact on cellular
gap junctions and relevant growth signaling pathways, while
moderately suppressing apoptosis, mismatch repair and the Ras-
Independent pathway in NK cell-mediated cytotoxicity, which is
overall an advantage to cell growth. LH, subsequently, regulated
gene expression involved in the cell cycle, p53 and VEGF
signaling, gap junction, immune responses and the complement
and coagulation cascades, as well as on a few metabolic pathways.
The transcriptome expression analysis reflects those pathway
alterations that support the phenotypes observed in our previous
study [14], as well as many others [15].
Prediction of microRNA/mRNA Regulation Pairs
Inference of microRNA function can be approached by
investigating the proteins and RNAs associated with the biological
processes in which their mRNA targets are involved. The
following strategy was adopted to first predict the potential
mRNA target(s) for each microRNA. Spearman correlation
analysis was performed between the expression of 65 differentially
expressed microRNAs associated with LHR expression and
activation and the expression of 60,860 well-annotated mRNAs
across all sample groups (Materials and Methods). Among all
possible microRNA-mRNA pairs, significant correlations were
detected using (|rho|.0.8, P-value,0.05), which includes 62,150
and 931,009 pairs of negative and positive correlations, respec-
tively. Figure 3 shows the distribution of the rho coefficient of both
experimental and predicted microRNA/mRNA pairs against all
calculated pairs, which indicates the significance of the interac-
tions.
We then examined those pairs of particular interest, with the
mRNAs differentially expressed in the LHR+ SKOV3 cells, i.e.
LHR+ and the same with LH incubation for 1, 4, 8 and20 h, since
our focus is on those that respond to LHR expression and
activation. In total, 19,105 negatively and 211,893 positively
correlated pairs are included, involving 19,154 unique mRNAs.
Figures 4A and 4B illustrate the top correlated pairs from each
group, most of which have not yet been experimentally validated.
Interestingly, more positively correlated microRNA-mRNA pairs
than negatively correlated pairs were observed for all microRNAs
Figure 1. Mapping of differentially expressed microRNAs to the human genome.
doi:10.1371/journal.pone.0021730.g001
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with the exception of nine, miR-181B2, miR-582, miR-497, miR-
559, miR-561, miR-101-1, miR-187, miR-572 and miR-301A
(Figure 5). The prevalence of high correlations may indicate that
the microRNA is intronic or upstream to the correlated gene since
they may share the same regulatory element and be transcribed
together, and thus do tend to predict physically proximate pairs.
The highly negative correlations are expected to indicate possible
biochemically important interactions.
We further examined the expressions between microRNA and
their host genes, which are generally concordant [35]. Among the
Figure 2. Distribution of the expression change of mRNAs in this study as cells express LHR and are activated by LH.
doi:10.1371/journal.pone.0021730.g002
Figure 3. Distribution of the correlation coefficients between microRNA and mRNA targets. (The blue plot represents the predicted
microRNA/mRNA pairs and the red plot represents the experimental validated pairs; the background plot in gray represents all pairs used for analysis
in this study).
doi:10.1371/journal.pone.0021730.g003
MiRNA Expression in Ovarian Carcinoma with LH
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Figure 4. The heatmap of the most correlated expressions between microRNA and mRNAs. A: pairs with the highest negative correlation
in expression, and B: pairs with the highest positive correlation in expression (|rho|.0.99).
doi:10.1371/journal.pone.0021730.g004
Figure 5. Comparison between the positively and negatively correlated pairs for each differentially-expressed microRNA (73
probes are involved for 65 unique microRNAs).
doi:10.1371/journal.pone.0021730.g005
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65 differentially expressed microRNAs, 13 intronic ones were
observed that are highly or moderately correlated with their host
genes, such as mir-555/ASH1L, mir-22/C17orf93, mir-198/
FSTL1, mir-561/GULP1 and mir-564/KIF15, 18 poorly corre-
lated and four negatively correlated with their host genes (Table
S3). One possible explanation for the poor correlations is that the
microRNAs may have their own regulatory elements rather than
sharing the same with their host genes. To confirm this possibility,
one can search for the transcriptional features in flanking
sequences of microRNA precursors such as transcription start
sites (TSS), CpG islands and transcription factor binding sites
(TFBS), compared to the same analysis on the host genes. The
very few observed negative correlations may be attributable to the
interference by the diverse expression of splice variants of the same
gene measured in this study. Of course, one cannot exclude the
possibility that some microRNAs may regulate their host gene
through the mRNA degradation machinery.
To ensure that the microRNA-correlated genes are direct
targets instead of downstream genes, two popular programs,
MiRanda [26] and TargetScan [27], were applied to predict
miRNA targets. 584 genes were predicted as potential targets of
the 65 microRNAs (see detailed list in Table S4). Although not all
predicted pairs possess high correlations, it does show a trend that
the percentage of predicted pairs decreased as the coefficients
increase along its distribution. With the cutoffs used above, only
155 genes were retained as high-confident ones, i.e. negatively
correlated with microRNA and differentially expressed, for
functional analysis.
MicroRNA Regulation Involved in LH Downstream
Signaling in LHR+ SKOV3 Cells
For each microRNA, the function and pathway enrichment
analysis was performed on its gene targets in order to infer the
main function of the miRNA. From Table S1, it is indicated, for
example, that miR-199b-5p participates in angiogenesis, nucleo-
tide excision repair, the PDGF signaling pathway, the cadherin/
Wnt/integrin signaling pathway, apoptosis and the MAPK
signaling pathway, according to its regulation of the transcrip-
tion/translation regulator and signaling transducer proteins
enriched in its target gene set. MiR-101 is also involved in the
Wnt/MAPK/cadherin signaling pathway, as well as hypertrophic
cardiomyopathy (HCM), melanogenesis, the metabotropic gluta-
mate receptor group III pathway and ubiquitin-mediated
proteolysis. In addition, it may also regulate to some extent the
mRNA for cyclic AMP (cAMP)-specific phosphodiesterase 4D
(PDE4D), which was found to be highly up-regulated by LH in
LHR+ cells [15]. MiR-29c is shown to mainly regulate ECM-
receptor interaction, focal adhesion, collagen a chains and the
integrin signaling pathway. The main regulation of miR-129 is
that of angiogenesis, the Wnt signaling pathway, transcription
regulation and cell junction. It is noteworthy that several of the
microRNAs have the potential to regulate various tyrosine and
serine/threonine kinases.
To further elucidate the microRNA regulation involved in LH-
treated cancer cells, 70 experimentally validated targets of the 65
differentially expressed microRNAs were examined according to
the miRecords database [36] (Table S1). Some of these genes were
differentially expressed in the response to LH binding to LHR+
cancer cells, including those involved in the regulation of cell
migration and proliferation (such as IRS1, IRS2, IL6R, TPM1,
GLI1, BMPR2 and GRN), cell surface receptor-linked signal
transduction (SOCS5 and RAF1), anti-apoptosis (FAS, MCL1 and
SGK3) and transcription regulation (DNMT3B, GLI1 and
EZH2), as shown in Table 1. Six genes exhibited highly correlated
expression to their microRNAs (|rho|.=0.7), including IRS1,
IRS2 and RAF1 to miR-7-1, SGK3 and MTAP to miR-21 and
GRN to miR-659. The negatively correlated microRNA/mRNA
pairs are of more interest in reflecting a direct interaction. It is
indicated from the expression changes that LH may impose a
moderate positive regulation of cell proliferation, nucleotide
metabolic process and cell surface receptor-linked signal trans-
duction, and a negative regulation of apoptosis on ovarian cancer
cells, in terms of the gene regulation through miR-7-1, miR-21
and miR-659. We also examined 54 oncogenes and tumor
suppressor genes derived from literature sources [30,37] (Table
S5). As listed in Table 2, only six genes have experimental or
predicted information. All the predicted targets are up-regulated
except one: up-regulation of miR-21 and down-regulation of its
target TPM1, a tumor suppressor gene. This may suggest a role of
miR-21 in inhibiting apoptosis and consequently inferring a
positive impact of LH on cancer development. Up-regulation of
NF1, RB1 and SUFU shows a negative effect on cancer growth,
consistent with our previous report [14].
Discussion
Numerous recent studies have reported that the global
expression of microRNAs is deregulated in most cancers, including
epithelial ovarian cancer [38]. We present here the first study
demonstrating that LH regulates microRNA expression in LHR+
SKOV3 cells. With the continuous exposure of LH to the LHR+
cells, the highly correlated expression patterns observed between
differential microRNAs and their target genes affirm the
underlying predicted interactions and were then applied for
inferring the involvement of microRNA regulation. One advan-
tage of using a disease-specific array is the gathering of highly
extensive mRNA data and microRNA information in ovarian
cancer on the same chip which largely avoids the technical noise
associated with profiling their expression in separate chips.
Prediction of microRNA and mRNA regulation pairs is clearly
a crucial component in this study, which is mainly through
correlation analysis in conjunction with collective computational
prediction. We first note the limitations of correlation analysis in
two regards: i) as the microRNAs fluctuate in the network, the
relative expression change in their target mRNAs may not be
concordant because of many other transcriptional regulation
mechanisms, and ii) an excess of high positive and negative
correlation pairs were observed, but most of them do not contain
sufficiently complementary sequences to predict a target relation-
ship, nor do they lie in physical proximity to each other. Clearly,
correlations alone are not adequate for accurate prediction, but
can be used as an auxiliary validation. Numerous computational
algorithms have been recently developed for predicting micro-
RNA/mRNA interactions based on information embodied in the
sequence and structure [39], including those used in this study. It is
known that microRNA binding to its target mRNA is through an
Argonaute (Ago)-containing effector complex, referred to as RISC
(RNA induced silencing complex), where Ago proteins plays a
central role in recognizing and binding to target mRNAs [40]. It is
therefore anticipated that a method taking into consideration the
sequence or structure information of AGO proteins may
significantly improve the prediction performance.
The results reported herein on the down-regulation of miR-
200c concomitant with LHR expression and activation are
particularly interesting in terms of a recent report on the analysis
of microRNAs in tumor tissues from patients with stage I epithelial
ovarian cancer [41]. It was found that down-regulation of
microRNA-200c correlated with overall survival, but the patients
MiRNA Expression in Ovarian Carcinoma with LH
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may be more susceptible to relapse. It is well recognized that the
microRNA family (200a, 200b, 200c, 141, 429) is important in
regulating metastasis [42]. Another study found that miR-22
correlated with inhibition of cancer cell migration and invasion
[43], so the down-regulated expression reflects the consistency
with our observations that the addition of LH to LHR+ SKOV3
cells inhibited cell proliferation, migration, and invasion [14].
Upregulation of miR-21 was observed in our study, which may be
caused by DNA hypomethylation as reported in vivo [44] and
shows consistency with the ovarian steroids regulation (ICI-182780
and MPA treatment) in myometrial and leiomyoma cells [45]. In
additional to those above, the most prominent and ‘‘hypoxia-
responsive’’ miRNA, miR-210, was found to be unregulated by
LH, which modulates the expression of genes promoting cell
survival and tumor growth under hypoxic condition [46].
We have previously shown that ligand-mediated activation of
LHR in the LHR+ SKOV3 cells activates second messenger
responses, cAMP and inositol phosphates [14], which initiate
protein kinase cascades that are involved with acute cellular
effects, e.g. steroidogenesis in steroidogenic cells and mitogenic
signaling [47,48]. It was also demonstrated that LH reduces cell
proliferation of LHR+ (but not LHR2) SKOV3 cells, as well as
cell migration and invasiveness [14]. In order to elucidate the
mechanism of this hormonal regulation, previous work has
established that LH is responsible for the transcriptional regulation
of a relatively large number of genes and pathways that could
explain the underlying cellular responses [15]. In this work,
microRNAs, as important gene regulators, were studied by
profiling the expression patterns and analysis of their target genes;
some of the microRNAs exhibit characteristics suggesting an
important role in regulating downstream LHR signaling in
ovarian cancer cells. Subsequent studies will be necessary to
determine the specific function of each such microRNA.
In summary, although the role of LH in the progression of
ovarian cancer is still controversial, it is well documented that LH-
mediated signaling affects many microRNAs, genes and pathways
in the LHR+ SKOV3 cells, and the indicative clues of inhibiting
apoptosis and regulating cell proliferation may direct further
research and help elucidate causes, detection and treatment of
ovarian cancer.
Supporting Information
Table S1 MicroRNAs differentially expressed in SKOV3 cells
with LHR expression and activation (including expression fold
change and target information).
(DOCX)
Table S2 14 pairs of closest neighbors from the differentially
expressed microRNAs identified in our data.
(XLSX)
Table S3 Correlated groups of microRNAs and their host genes.
(XLSX)
Table S4 Predicted gene targets for each microRNA by both
MiRanda and TargetScan.
(XLSX)
Table S5 Correlation between microRNAs and cancer genes.
(XLSX)
Author Contributions
Conceived and designed the experiments: JC DP. Performed the
experiments: JC JE. Analyzed the data: JC JE YX. Contributed
reagents/materials/analysis tools: DP YX. Wrote the paper: JC DP.
References
1. http://www.cancer.org American Cancer Society. Last Revised: 10/13/2010 ed.
2. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003) Survival and
prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:
885–891.
3. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, et al. (1975-2007)
SEER Cancer Statistics Review. In: Institute NC, ed. Bethesda, MD.
4. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, et al. (2002)
Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control
studies. Am J Epidemiol 155: 217–224.
5. Kramer S, Leeker M, Jager W (1998) Gonadotropin levels in ovarian cyst fluids:
a predictor of malignancy? Int J Biol Markers 13: 165–168.
6. Kwintkiewicz J, Giudice LC (2009) The interplay of insulin-like growth factors,
gonadotropins, and endocrine disruptors in ovarian follicular development and
function. Semin Reprod Med 27: 43–51.
7. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, et al. (2004)
Focus on epithelial ovarian cancer. Cancer Cell 5: 19–24.
8. MosgaardBJ,LidegaardO,KjaerSK,SchouG,AndersenAN(1997) Infertility, fertility
drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67: 1005–1012.
9. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, et al. (2009)
Ovarian epithelial neoplasia after hormonal infertility treatment: long-term
follow-up of a historical cohort in Sweden. Fertil Steril 91: 1152–1158.
10. Huhtaniemi I (2010) Are gonadotrophins tumorigenic–a critical review of
clinical and experimental data. Mol Cell Endocrinol 329: 56–61.
11. Leung PC, Choi JH (2007) Endocrine signaling in ovarian surface epithelium
and cancer. Hum Reprod Update 13: 143–162.
12. Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, et al. (2008) SEER
Cancer Statistics Review. In: National Cancer Institute, Bethesda M, ed.
13. Choi JH, Wong AS, Huang HF, Leung PC (2007) Gonadotropins and ovarian
cancer. Endocr Rev 28: 440–461.
14. Warrenfeltz SW, Lott SA, Palmer TM, Gray JC, Puett D (2008) Luteinizing
hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and
invasion in ovarian cancer cells. Mol Cancer Res 6: 1775–1785.
Table 2. Correlation of expression between ovarian cancer-associated microRNA and their target oncogenes (q andQ represent,
respectively, the up-regulation and down-regulation of gene expression in response to LH treatment, ‘‘2’’ means that no
significant expression change was observed).
microRNA Oncogenes Gene name Target (rho)
Mir-21 (q) TPM1 (Q) tropomyosin 1 (alpha) known 20.24
microRNA 103-1(q) NF1(q) neurofibromin 1 predicted 0.94
microRNA 7-3 (2) RB1(q) retinoblastoma 1 predicted 0.68
microRNA 103-1(q) SUFU(q) suppressor of fused homolog (Drosophila) predicted 0.89
microRNA 103-1(q) CDK6(2) cyclin-dependent kinase 6 predicted 0.04
microRNA 181b-2(Q) SOX5(2) SRY (sex determining region Y)-box 5 predicted 20.43
doi:10.1371/journal.pone.0021730.t002
MiRNA Expression in Ovarian Carcinoma with LH
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21730
15. Cui J, Miner B, Eldredge JB, Warrenfeltz SW, Xu Y, et al. (2011) Gene
Expression Profiling of Ovarian Cancer Cells: Alterations by Luteinizing
Hormone Receptor Activation. BMC Cancer (in press).
16. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
17. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350–355.
18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A
MicroRNA signature associated with prognosis and progression in chronic
lymphocytic leukemia. N Engl J Med 353: 1793–1801.
19. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006)
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.
Cancer Cell 9: 189–198.
20. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, et al. (2007)
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from
normal pancreas and chronic pancreatitis. JAMA 297: 1901–1908.
21. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, et al. (2008)
MicroRNA expression profiles associated with prognosis and therapeutic
outcome in colon adenocarcinoma. JAMA 299: 425–436.
22. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, et al. (2008)
MicroRNA signatures associated with cytogenetics and prognosis in acute
myeloid leukemia. Blood 111: 3183–3189.
23. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O’Briant K, et al. (2009)
Repertoire of microRNAs in epithelial ovarian cancer as determined by next
generation sequencing of small RNA cDNA libraries. PLoS One 4: e5311.
24. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic
profiling of microRNA and messenger RNA reveals deregulated microRNA
expression in prostate cancer. Cancer Res 68: 6162–6170.
25. Croce CM (2009) Causes and consequences of microRNA dysregulation in
cancer. Nat Rev Genet 10: 704–714.
26. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, et al. (2006) A pattern-based
method for the identification of MicroRNA binding sites and their correspond-
ing heteroduplexes. Cell 126: 1203–1217.
27. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell
120: 15–20.
28. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ (2006)
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids
Res 34: D140–144.
29. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human
microRNA genes are frequently located at fragile sites and genomic regions
involved in cancers. Proc Natl Acad Sci U S A 101: 2999–3004.
30. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, et al. (2010)
Signatures of mutation and selection in the cancer genome. Nature 463:
893–898.
31. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, et al. (2000) ARHI is the
center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
Int J Cancer 86: 690–694.
32. Barlund M, Monni O, Kononen J, Cornelison R, Torhorst J, et al. (2000)
Multiple genes at 17q23 undergo amplification and overexpression in breast
cancer. Cancer Res 60: 5340–5344.
33. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A
microRNA polycistron as a potential human oncogene. Nature 435: 828–833.
34. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent
deletions and down-regulation of micro- RNA genes miR15 and miR16 at
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:
15524–15529.
35. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of
mammalian microRNA host genes and transcription units. Genome Res 14:
1902–1910.
36. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated
resource for microRNA-target interactions. Nucleic Acids Res 37: D105–110.
37. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, et al. (2009) miR2Disease: a
manually curated database for microRNA deregulation in human disease.
Nucleic Acids Res 37: D98–104.
38. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, et al. (2008) Genomic
and epigenetic alterations deregulate microRNA expression in human epithelial
ovarian cancer. Proc Natl Acad Sci U S A 105: 7004–7009.
39. Dai Y, Zhou X (2010) Computational methods for the identificaiton of
microRNA targets. Open Access bioinformatics 2010: 29–39.
40. Wang Y, Li Y, Ma Z, Yang W, Ai C (2010) Mechanism of microRNA-target
interaction: molecular dynamics simulations and thermodynamics analysis.
PLoS Comput Biol 6: e1000866.
41. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, et al. (2011)
Association between miR-200c and the survival of patients with stage I epithelial
ovarian cancer: a retrospective study of two independent tumour tissue
collections. Lancet Oncol 12: 273–285.
42. Li SD, Zhang JR, Wang YQ, Wan XP (2010) The role of microRNAs in ovarian
cancer initiation and progression. J Cell Mol Med 14: 2240–2249.
43. Li J, Liang S, Yu H, Zhang J, Ma D, et al. (2010) An inhibitory effect of miR-22
on cell migration and invasion in ovarian cancer. Gynecol Oncol 119: 543–548.
44. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA
signatures in human ovarian cancer. Cancer Res 67: 8699–8707.
45. Pan Q, Luo X, Chegini N (2008) Differential expression of microRNAs in
myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol
Med 12: 227–240.
46. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, et al. (2009)
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in
tumor initiation. Mol Cell 35: 856–867.
47. Rozengurt E (2007) Mitogenic signaling pathways induced by G protein-coupled
receptors. J Cell Physiol 213: 589–602.
48. Ascoli M, Puett D (2009) The gonadotropin hormones and their receptors.
Philadelphia (PA): Elsevier Publishing.
MiRNA Expression in Ovarian Carcinoma with LH
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21730
